Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated αβ T-cells

Ishii F1, Yoshida Y2, Yamauchi Y1, Aisu N1, Kojima D1, Mera T1, Kato D1, Tanaka T3, Naito K4, Yasumoto K4, Kamigaki T4, Goto S4, Hamada Y5, Nimura S5, Kodama S6, Hasegawa S1.

Anticancer Res. 2017 Jul;37(7):3933-3939.

Abstract

BACKGROUND/AIM:

Various types of chemoimmunotherapies for malignant tumors have been reported. However, there are few reports on hepatectomy after chemoimmunotherapy. We evaluated the safety and efficacy of hepatectomy for patients with stage IV colorectalliver metastases (CLM) after chemoimmunotherapy using activated αβ T-cells.

PATIENTS AND METHODS:

From June 2012 to December 2016, five patients who underwent hepatectomy after receiving capecitabine and oxaliplatin (XELOX) plus bevacizumab and ex vivo-expanded αβ T-lymphocytes as first-line chemoimmunotherapy were included.

RESULTS:

The median age of the five patients (two men, three women) was 61.4 (range=56-75) years. The surgical procedure was partial hepatectomy in two, laparoscopic partial hepatectomy in two, and one case of partial hepatectomy with subsegmentectomy. There was no postoperative complication of Clavien-Dindo grade 3A or higher. One patient had multiple lung metastases.

CONCLUSION:

Hepatectomy after chemoimmunotherapy using activated αβ T-cells for CLM can be performed safely.